OBJECTIVE： To evaluate the effects of PDCA cycle management method on clinical application of Fat-soluble vitamin for injection （Ⅱ）. METHODS： By retrospective analysis， 500 discharge medical records of Fat-soluble vitamin for injection （Ⅱ） were collected from our hospital during Jul.-Aug. in 2015 （before intervention）， Sep.-Oct. in 2015 （after first intervention cycle）， Nov.-Dec. in 2015 （after second intervention cycle）， respectively. RESULTS： After 2 PDCA cycles， the proportion Fat-soluble vitamin injection （Ⅱ） use without indication decreased from 65.4％ to 39.2％； the reasonable rate of drug dosage increased from 53.2％ to 97.2％， and that of usage increased from 96.4％ to 99.8％； the reasonable rate of medication course increased from 69.6％ to 96.6％； the reasonable rate of the clinical application of Fat-soluble vitamin injection （Ⅱ） increased from 18.8％ to 56.4％， with statistical significance （P＜0.05）. CONCLUSIONS： PDCA cycle can effectively promote the clinical reasonable of Fat-soluble vitamin for injection （Ⅱ） .